Study #2023-0706
A phase 1b multicenter, open-label, study of JNJ-90009530, an autologous anti-CD20 CAR-T cell therapy in adult participants with relapsed or refractory B-cell Non-Hodgkin lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
JNJ-90009530
Description
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Study phase:
Phase I
Physician name:
Sairah Ahmed
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-866-253-6411
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.